Lymphadenopathy/splenomegaly or lymphocyte doubling time and CD38 percentages or soluble APO1/Fas levels
| . | Lymphadenopathy/splenomegaly . | LDT* . | ||
|---|---|---|---|---|
| Present (n = 65) . | Absent (n = 103) . | Less than 12 mo (n = 14) . | More than 12 mo (n = 154) . | |
| CD38† | ||||
| More than 30% (n = 50) | 86.0% (73.3-94.2)2-153 | 14.0% (5.8-26.7) | 71.4% (41.9-91.6) | 28.6% (8.4-58.1) |
| Less than 30% (n = 118) | 18.6% (12.1-26.9) | 81.3% (73.1-87.9) | 26% (19.2-33.6) | 74% (66.3-80.7) |
| sAPO1/Fas‡ | ||||
| More than 7 ng/mL (n = 68) | 52.9% (40.4-65.1) | 47.1% (34.8-59.5) | 77.8% (39.9-97.2) | 22.2% (2.8-60) |
| Less than 7 ng/mL (n = 93) | 25.8% (17.3-35.9) | 74.2% (64.1-82.7) | 40.1% (32.3-48.4) | 59.8% (51.6-67.7) |
| . | Lymphadenopathy/splenomegaly . | LDT* . | ||
|---|---|---|---|---|
| Present (n = 65) . | Absent (n = 103) . | Less than 12 mo (n = 14) . | More than 12 mo (n = 154) . | |
| CD38† | ||||
| More than 30% (n = 50) | 86.0% (73.3-94.2)2-153 | 14.0% (5.8-26.7) | 71.4% (41.9-91.6) | 28.6% (8.4-58.1) |
| Less than 30% (n = 118) | 18.6% (12.1-26.9) | 81.3% (73.1-87.9) | 26% (19.2-33.6) | 74% (66.3-80.7) |
| sAPO1/Fas‡ | ||||
| More than 7 ng/mL (n = 68) | 52.9% (40.4-65.1) | 47.1% (34.8-59.5) | 77.8% (39.9-97.2) | 22.2% (2.8-60) |
| Less than 7 ng/mL (n = 93) | 25.8% (17.3-35.9) | 74.2% (64.1-82.7) | 40.1% (32.3-48.4) | 59.8% (51.6-67.7) |